Exclusion Criteria:~1. Abnormalities in vital signs at screening or baseline~2. Clinically significant abnormal
hematology or biochemistry values, as determined by the investigator at screening and/or baseline.~3. Previous
clinically significant systemic illness or infection within the past 4 weeks prior to screening or baseline, as
determined by the investigator~4. Clinically significant ECG abnormalities~5. Use of tobacco- or
nicotine-containing products in the past month or unwillingness to abstain during study participation~6.
Participation in another clinical study of a drug or device~7. Known allergy to the study drug (XanamemÂ®) or
any of the excipients~8. Subjects who are likely to be unable to comply with the study schedule and/ or
subjects with an inability to communicate well with the investigator~9. Positive testing for human
immunodeficiency virus (HIV), hepatitis B surface antigen, or hepatitis C antibodies at screening~10. Subjects
with a history of drug abuse or addiction in the past 5 years.~11. Evidence of alcohol abuse (defined as
greater than 21 standard units per week for males and greater than 14 standard units per week for females)
